Medincell Receives $19 Million Grant for Its mdc-WWM Program
28 Novembre 2019 - 5:45PM
Business Wire
The agreement with the Bill & Melinda Gates Foundation
provides that MedinCell owns the marketing rights of the product
worldwide, particularly in the United States.
French company MedinCell (Paris:MEDCL) and the Bill
& Melinda Gates Foundation have signed an agreement for up to
an additional $19 million to be granted over four years. It aims to
fund preclinical activities and a phase 1 clinical trial for the
injectable six-month bioresorbable contraceptive (mdc-WWM). The
grant is structured in advanced installments to cover the costs
that will be incurred by the project. Depending on the options
chosen and on the advancement of the program, up to $11.75 million
could be raised over the next 12 months including a first tranche
of $4.75 million to be paid immediately. The additional $7.25
million may be collected later.
As a reminder, a previous grant of $3.5 million was awarded
in November 2017 by the Gates Foundation to fund the formulation
research phase. Full results should make it possible to select the
candidate formulation.
MedinCell owns all marketing rights of the product worldwide,
including the United States where the contraceptive market totaled
more than $5 billion in 2018. Long-acting reversible contraceptives
(LARC) alone (primarily solid implants and intrauterine devices)
represented 28% of this market - more than $1.4 billion – with a
5-year CAGR at 7.8%. The mdc-WWM product could capture a
significant share of this LARC market and even expand it easing the
adoption of this type of contraception1.
In accordance with the Global Access strategy of both
partners and to ensure a significant impact on women’s lives, the
objective is to make the product widely available. Affordable
pricing in emerging economies will help eliminate cost as a barrier
to increased availability and voluntary access to the product. High
demand among women and girls for long-acting contraceptive options
illustrate the potential for market growth and measurably improving
maternal, newborn and child health. The Gates Foundation also has a
non-exclusive license for non-commercial market in low- and
middle-income countries.
___________________________________________________________________________________________________________________________________________________
mdc-WWM could be the first contraceptive to combine the
following essential features to make it a best-in-class product
worldwide: progestin molecule (non-MPA), 6-month duration,
subcutaneous injection, full bio-resorption, affordability.
The Gates Foundation supports the development of products to
enhance health outcomes of the world’s most vulnerable populations.
An estimated 74 million women fall pregnant unintentionally every
year leading to
25 million unsafe abortions and 47,000 maternal deaths2.
Increasing access to efficient contraceptive solutions, coupled
with family planning information and services, aims to reduce
unintended pregnancies, deaths from pregnancy and childbirth,
abortion rates and lead to fewer infant deaths. It also aims to
improve educational and economic opportunities for women, and
foster healthier families and communities.
mdc-WWM could indeed address major challenges such as low
affordability, weak distribution systems or cultural barriers.
Unlike most LARCs such as contraceptive implants, no surgical or
specialist intervention will be necessary with MedinCell’s product.
After a simple subcutaneous injection a deposit is formed, acting
as a virtual-pump for up to 6 months, which then disappears
completely. Studies have shown that the risk of contraceptive
failure in women receiving oral contraceptive or other methods is
17 to 20 times higher than using a long-acting reversible
contraceptives (LARC), mainly because of the lack of
compliance3.
mdc-WWM would be the sixth product based on MedinCell’s
technology to enter preclinical development. All products use
already approved active ingredients with demonstrated safety and
efficacy, significantly increasing the chances of success.
___________________________________________________________________________________________________________________________________________________
About MedinCell
MedinCell is a clinical stage pharmaceutical company that
develops a portfolio of long-acting injectable products in various
therapeutic areas by combining its proprietary BEPO® technology
with active ingredients already known and marketed. Through the
controlled and extended release of the active pharmaceutical
ingredient, MedinCell makes medical treatments more efficient,
particularly thanks to improved compliance, i.e. compliance with
medical prescriptions, and to a significant reduction in the
quantity of medication required as part of a one-off or chronic
treatment. The BEPO® technology makes it possible to control and
guarantee the regular delivery of a drug at the optimal therapeutic
dose for several days, weeks or months starting from the
subcutaneous or local injection of a simple deposit of a few
millimeters, fully bioresorbable. Based in Montpellier, MedinCell
currently employs more than 130 people representing over 25
different nationalities.
www.medincell.com
1 Source: IQVIA 2 Source: WHO - Oct. 2019 3 Winner, B; Peipert,
JF; Zhao, Q; Buckel, C; Madden, T; Allsworth, JE; Secura, GM.
(2012), “Effectiveness of Long-Acting Reversible Contraception”,
New England Journal of Medicine, 366 (21): 1998–2007,
doi:10.1056/NEJMoa1110855, PMID 22621627
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191128005494/en/
MedinCell David
Heuzé Communication
leader david.heuze@medincell.com +33 (0)6 83 25 21 86
NewCap Louis-Victor
Delouvrier / Alexia Faure Investor relations medincell@newcap.eu
+33 (0)1 44 71 94 94
NewCap Nicolas
Merigeau Media
relations medincell@newcap.eu +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Medincell (EU:MEDCL)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024